Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;38(7):1357-1364.
doi: 10.1007/s00381-022-05543-2. Epub 2022 Apr 30.

Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children

Mehmet Tolga Köle  1 , Safiye Günes Sager  2 , Hatice Zeynel  2 , Yakup Çağ  2 , Yasemin Akın  2
Affiliations

Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children

Mehmet Tolga Köle et al. Childs Nerv Syst. 2022 Jul.

Abstract

Purpose: Phenytoin is one of the most used antiepileptic drugs (AEDs), but it has serious potential side effects and drug interactions. Although studies have shown levetiracetam to have a much lower side-effect profile, its efficacy when compared with phenytoin is debatable. In our study, we aimed to determine the factors that cause seizure recurrence and to compare the efficacy of levetiracetam and phenytoin in the treatment of convulsive status epilepticus (CSE) and acute repetitive seizures (ARS).

Methods: In this study, 185 patients diagnosed with CSE or ARS and aged between 1 month and 18 years who received intravenous levetiracetam or phenytoin as a second-line AED were retrospectively evaluated.

Results: A total of 185 patients were included in the study, 85 (45.9%) girls and 100 (54.1%) boys.While 54.1% (n = 100) of the patients were given phenytoin, levetiracetam was administered to 45.9% (n = 85) of them. The rates of cessation of seizure and prevention of seizure recurrence for 24 h were 84% for phenytoin and 78.8% for levetiracetam, without a significant difference (p > 0.05). Having active seizures on admission to the emergency department and an age of < 36 months were significantly related to seizure recurrence (p < 0.01).

Conclusions: Our results support that the intravenous administration of levetiracetam as the second-line treatment for CSE and ARS in children is as effective as the intravenous administration of phenytoin.

Keywords: Children; Levetiracetam; Phenytoin; Seizures; Status epilepticus.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Lee YJ, Yum MS, Kim EH, Ko TS (2016) Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures. Korean J Pediatr 59(1):35–39. https://doi.org/10.3345/kjp.2016.59.1.35 - DOI - PubMed - PMC
    1. Besli GE, Yuksel Karatoprak E, Yilmaz S (2020) Efficacy and safety profile of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. Epilepsy Behav 111:107289. https://doi.org/10.1016/j.yebeh.2020.107289 - DOI - PubMed
    1. Vanhaerents S, Gerard EE (2019) Epilepsy emergencies: status epilepticus, acute repetitive seizures, and autoimmune encephalitis. Contin Lifelong Learn Neurol 25(2):454–476. https://doi.org/10.1212/CON.0000000000000716 - DOI
    1. Lyttle MD, Rainford NEA, Gamble C et al (2019) Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 393(10186):2125–2134. https://doi.org/10.1016/S0140-6736(19)30724-X - DOI - PubMed - PMC
    1. Sculier C, Gaínza-Lein M, Sánchez Fernández I, Loddenkemper T (2018) Long-term outcomes of status epilepticus: a critical assessment. Epilepsia 59:155–169. https://doi.org/10.1111/epi.14515 - DOI - PubMed - PMC

LinkOut - more resources